Valeant also announced that its Bausch & Lomb Inc. subsidiary received Food and Drug Administration clearance for sales of a device used in cataract surgery. Messages Meanwhile, Ackman sent two separate messages to Allergan's board—a letter and a webcast, both made public—complaining over its cool response to Valeant's bids and the bylaws that make it difficult to call a special meeting of shareholders. Valeant's shares were up less than 1% for the week as the end of the trading day neared on Friday. That put its offer at about $51.5 billion—still short of the range of expectations among analysts and shareholders, according to recent reports. Another possible hurdle for Valeant could surface at anytime, with Allergan on the hunt for an acquisition that could put it out of reach altogether.